NHS spends nearly £500m on cancer drugs developed with public funding

By agency reporter
February 5, 2019

Health campaigners have called for the government to make major changes to the way medicines are researched and developed, after new analysis of the cost of leading cancer drugs to the NHS showed that £458 million was spent in 2017/18 on paying pharmaceutical companies for medicines developed with public funding. 

The figures, released by the Missing Medicines Coalition on World Cancer Day, show that three of the five most expensive cancer drugs to the NHS last year were developed from publicly-funded research. As a result the public are paying twice for medicines – first for the research and then in high prices to the drug industry. The publicly-researched cancer drugs include:

  • Trastuzumab, owned by Swiss multinational Roche, used to treat breast cancer. NHS England spent £163 million on buying the drug in 2017-18.
  • Rituximab, used to treat non-Hodgkin lymphoma and chronic lymphocytic leukaemia. £153 million was paid for the drug last year, also to Roche.
  • Pembrolizumab, a drug owned by US drug giant Merck, used to treat some people with non small cell lung cancer, skin cancer and Hodgkin lymphoma. The NHS spent £142 million on this drug.

The basic technologies for producing all three of these medicines were developed by Greg Winter in the 1980s and 1990s, predominantly at the UK Medical Research Council Laboratory of Molecular Biology (MRC LMB) in Cambridge. The MRC LMB is funded primarily by the UK Medical Research Council.

NHS England spent a record £18.2 billion on medicines in 2017-18, up 28 per cent since 2010. The medicines bill is still rising faster than the NHS budget even after the increases pledged by the Chancellor over the next five years in his autumn budget.

In December, a World Health Organisation technical report found that the pricing of cancer drugs is disproportionately higher than other types of pharmaceuticals and therapies around the world. It identified that pharmaceutical companies set prices not based on the costs of research and development, but rather according to “commercial goals, with a focus on extracting the maximum amount that a buyer is willing to pay for a medicine”, which “makes cancer medicines unaffordable, preventing the full benefit of the medicines from being realised.” 

Radhika Patel, campaigner at Global Justice Now, said: “Millions of people across the country run marathons, make donations or volunteer their time to help the fight against cancer, and every penny counts. So why is the government letting big pharma charge such vast amounts for drugs where public funding has paid for research? Medical research needs first and foremost to serve people, not lay the ground for pharmaceutical company profits. It is time for ministers to turn the corporate-driven model of drug production on its head and put people’s right to health first.”

Saoirse Fitzpatrick from STOPAIDS, coordinator of the Missing Medicines Coalition, said: “The government is always talking about value for money, well this is an area where we could be saving money and lives. The public are footing the bill for the riskiest part of drug development where breakthroughs happen. Then the big pharmaceutical companies swoop in, patent a medicine and use the monopoly to charge the public an extortionate price. This leads to crucial treatments being delayed and at times denied to patients in need. It’s time for things to change. Many governments are now looking at how we ensure that publicly funded medicines are affordable to patients and health systems -  the Missing Medicines coalition is calling on the UK Government to follow suit.”

Diarmaid McDonald from Just Treatment said: “More and more NHS patients are being forced to fundraise to pay for medicines or organise public campaigns to secure access to essential treatments as pharma’s completely unaffordable prices lead to rationing and rejection of proven treatments. On World Cancer Day, the government needs to commit to doing much more than haggling on price and giving up if drug companies refuse to budge – it needs to make big structural changes to medical innovation that put patients before profit.”

The call follows a report by the organisations in October calling for major changes to health innovation to deliver public value, including:

  • Conditions to be attached to medical funding to guarantee a public return on public investment
  • The use of government-funded prizes for medical innovation to delink the discovery of new treatments from the need to charge high prices.
  • Use of WTO rules on compulsory licensing by the UK government to enable emergency access to medicines 

The NHS has increasingly rationed or refused drugs in recent years because of high prices. In 2017 breast cancer drug palbociclib was turned down by the NHS for being too expensive, but was later licenced after drug giant Pfizer came under pressure to lower the cost. UK patients cannot access the cystic fibrosis drug Orkambi because of the £104,000 per year price demanded by its manufacturer, Vertex Pharmaceuticals, despite years of negotiations. And spinal muscular atrophy (SMA) treatment Spinraza was rejected in August last year on value for money grounds, despite it being licensed in Europe and the US.

The Missing Medicines coalition, coordinated by STOPAIDS, is a network of STOPAIDS members and other organisations committed to ensuring people everywhere get the medicines they need at prices they can afford.

* Missing Medicines Coalition http://missingmedicines.co.uk/

* Global Justice Now https://www.globaljustice.org.uk/

[Ekk/6]

Although the views expressed in this article do not necessarily represent the views of Ekklesia, the article may reflect Ekklesia's values. If you use Ekklesia's news briefings please consider making a donation to sponsor Ekklesia's work here.